Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer

This publication has 15 references indexed in Scilit:

• Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)
  European Journal of Cancer, 2015
• Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer
  European Journal of Cancer, 2015
• Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest
  Annals of Oncology, 2015
• PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
  Journal of Clinical Oncology, 2014
• Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
  The Lancet Oncology, 2014
• Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
  New England Journal of Medicine, 2013
• BRAF Mutation Status and Survival after Colorectal Cancer Diagnosis According to Patient and Tumor Characteristics
  Cancer Epidemiology, Biomarkers & Prevention, 2012
• Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
  The Lancet Oncology, 2010
• New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
  European Journal of Cancer, 2009
• Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
  Journal of Clinical Oncology, 2008